Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sarcoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Nivolumab 37pembrolizumab 26cabozantinib 26Specimen Handling 23Magnetic Resonance Spectroscopy 21Ipilimumab 19lenvatinib 13belzutifan 13Axitinib 13CTLA-4 Antigen 10Sunitinib 9Radiosurgery 8Biopsy 8atezolizumab 7fludarabine 4avelumab 4aldesleukin 4Immunoglobulin G 4Disulfides 4zimberelimab 3toripalimab 3tivozanib 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3Surveys and Questionnaires 3Nephrectomy 3Everolimus 3Cyclophosphamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Metastasectomy × 90 days × Clear all
NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
104 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡